What makes the Legacinetics approach unique, and how does it address the major biological functions of AD, neuro inflammation and other metabolic indications?
The starting cell-line includes rare and highly AD protective genetic alleles (APOE2). This genetic trait (7% of world population) provides superior inherent AD protection, superior neuronal support, amyloid clearance and longevity.
Starting lines undergo the IPSC conversion, based on the Nobel Prize (2012) winning process, with cells to embryonic stage.
Highly protective IPSC cells are gene-modified to specifically target key biomechanical functions that are proven to impact AD, neuroinflammation and metabolic dysfunction. Note that the biological pathways affected are broadly regenerative beyond AD.
These advanced gene-edited cells are then differentiated to all important MSC (Mesenchymal Stem Cells) – providing significant regenerative and amyloid clearing capacity via paracrine and immune-modulation functions.
Exosomes are extracted, providing a cell-free (no risk of rejection) and highly concentrated therapy, which can be administered intravenously, intrathecally, intranasal and intraarticular. Alternate administration pathways are identified for additional efficacy.
Legacinetics is commercialising dual-platform iPSC-derived iMSC exosome technology to deliver transformative therapies for Alzheimer’s, neuroinflammation, and metabolic diseases. Building on existing autologous IP and extensive real-world patient outcomes across a range of related indications, combined with a pathway to provisional patent, the company is creating both highly personalised treatments and scalable ‘off-the-shelf’ solutions.
With shared global experience across major markets including Australia, China, India, Thailand, New Zealand, Japan, UAE & Africa, the Legacinetics story is one of a shared vision of accelerated human wellness, scientific advances and global academic influence and leadership.
Legacinetics was founded by Professor Rajneesh Verma PhD, and James Scuderi, who together lead a team of highly experienced scientists, technicians and regenerative health practitioners from across the world.
Whether you're interested in our services, seeking partnerships, or simply want to learn more about what we do, our team is here to assist! Contact us to discuss how you can benefit from partnering with Legacinetics.
